LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… ProQR Announces R&D Day in New York on June 15 Key updates: ProQR to host an … Usher syndrome and other DEB mutations An introduction to ProQR’s novel RNA editing platform technology called Axiomer … ready to enter development,” said Daniel de Boer, CEO of ProQR. “We’re looking forward to provide an update on the …
… ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific … medicine platform from David Rodman, MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, … provide strategic direction, oversight, and execution for ProQR’s research and early development efforts. This entails …
… ProQR to Present at Scientific and Investor Conferences in … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at Upcoming JMP Securities Life Sciences … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Eve n ts ”. The archived webcast will …
… ProQR to Present at Upcoming Scientific Meeting and Investor … at 9:30am EST, Daniel de Boer, Chief Executive Officer of ProQR, will present at the LEERINK 7 th Annual Global … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and …
… ProQR Announces Financial Results for the Third Quarter of … LCA10,” said Daniel A. de Boer, chief executive officer of ProQR. “These results build confidence in QR-110 and the … for QR-110 in patients with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: …
